The Sixteenth John Vane Memorial Symposium (2021) on Prostacyclin Science and Pulmonary Vascular Disease

11-12 March 2021

research models

The John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held virtually for the first time in its sixteen-year history.  We are pleased this allowed for a wider audience but are very much looking forward to welcoming you back to the Royal Society, London in 2022.

 

In the meantime, those of you who attended this year will be able to revisit the presentations using the links below (your password will be emailed to you).  We hope you enjoy!

Roberto Badagliacca: Risk Reduction and Haemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension

 

Michele D’Alto: Risk Reduction and Right Heart Reverse Remodelling by Upfront Triple Combination Therapy in PAH

 

Anna Hemnes: Patient Stratification in PAH

 

Irene Lang: Advances in Balloon Pulmonary Angioplasty for the treatment of non-operable CTEPH

 

Sarah MacRae: Palliative Care in PAH

 

Nick Morrell: Polyamines and PAH

 

Robert Naeije: Non-Invasive Methods to assess PAH

 

Steven Nathan: Pulmonary Hypertension in Chronic Lung Disease

 

Olivier Sitbon: Emerging Endpoints in PAH

 

David Smadja: Prostacyclin Analogues and Non-Vasodilator Effects: Is there any Antithrombotic Effect in PAH?

 

Khodr Tello: Evaluation and Prognostic Relevance of Right Ventricular-Arterial Coupling in Pulmonary Hypertension

 

Chris Thiemermann: Welcome

 

Mark Toshner: Targeting Inflammation in PAH: Twist, Stick or Fold?

 

Raman Venkataramanan:  Prostacyclins to Protect Ischaemia and Reperfusion Injury of Organs for Transplantation

 

Dario Vizza: Afterload Reduction in the Early Use of Prostacyclin

 

Jim White: What have we learnt today?

 

Jim White: Getting the Most out of the 6-Minute Walk

Website design and development by Adept Lab photography by: Gary Shwartz